Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Aventis Pharmaceuticals
Rhone-Poulenc Rorer
Information provided by (Responsible Party):
University of Michigan Cancer Center
ClinicalTrials.gov Identifier:
NCT00148070
First received: September 2, 2005
Last updated: October 3, 2012
Last verified: October 2012

September 2, 2005
October 3, 2012
March 1999
September 2004   (final data collection date for primary outcome measure)
To assess whether assignment of docetaxel dose based on the ERMBT will result in decreased variability in drug area under the curve when compared to dosing based on body surface area. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
To assess whether assignment of docetaxel dose based on the ERMBT will result in decreased variability in drug area under the curve when compared to dosing based on body surface area.
Complete list of historical versions of study NCT00148070 on ClinicalTrials.gov Archive Site
To evaluate the safety and efficacy of tailored-dose docetaxel in metastatic breast cancer. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
To evaluate the safety and efficacy of tailored-dose docetaxel in metastatic breast cancer.
Not Provided
Not Provided
 
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's height and weight. However, some patients metabolize chemotherapy faster or slower than the average person because of a different level of drug metabolizing enzyme in the liver. Therefore, some patients are either given too small or too large a dose of chemotherapy because the amount of enzyme is not taken into account. This research study will examine the use of a simple test, call the Erythromycin Breath Test(ERMBT) to determine the amount of enzyme which can metabolize the chemotherapy drug docetaxel (Taxotere). The dose of docetaxel will be tailored to the amount of enzyme which is available to metabolize the drug for each patient.

This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's height and weight. However, some patients metabolize chemotherapy faster or slower than the average person because of a different level of drug metabolizing enzyme in the liver. Therefore, some patients are either given too small or too large a dose of chemotherapy because the amount of enzyme is not taken into account. This research study will examine the use of a simple test, call the Erythromycin Breath Test(ERMBT) to determine the amount of enzyme which can metabolize the chemotherapy drug docetaxel (Taxotere). The dose of docetaxel will be tailored to the amount of enzyme which is available to metabolize the drug for each patient. Patients participating in this study will have biopsy proven, measurable metastatic breast cancer.

During the study:

-Patients will receive tailored-dose docetaxel for their breast cancer.

Approximately 45 subjects will be recruited at this site.

Diagnosis and Staging

•All patients will have primary tumor measurements by physical exam and/or radiographic studies (CT, MRI, bone scan).

Erythromycin Breath Test* •The ERMBT will be administered in the outpatient setting, prior to the first cycle of docetaxel. Twenty minutes after the injection of a trace amount of (14C N-methyl) erythromycin, (This test assesses the activity of the cytochrome P450 enzyme which is largely responsible for the metabolism of the chemotherapeutic agent docetaxel.)patients will exhale through a tube creating bubbles in a solution of hyamine hydroxide, ethanol, and a blue indicator until 2 mmol of carbon dioxide has been trapped and the blue color vanishes.

Premedications

  • Dexamethasone 8 mg po bid for three days, beginning the day prior to docetaxel administration.
  • Diphenhydramine 50 mg IVPB
  • Granisetron 2 mg po 30 minutes pre-docetaxel

Chemotherapy

  • Docetaxel, tailored dose, to be infused over 1 hour on day 1 every 3 weeks for the duration of study.
  • Starting dose of docetaxel to be determined by the ERMBT and serum albumin according to formula as stated in protocol (page 11).

Suggested post-chemotherapy antiemetics:

•Compazine 10 mg po q 6 hours prn nausea/vomiting

Pharmacokinetic Analysis

•All patients will have pharmacokinetic determination with blood drawn for pharmacokinetic analysis over a 24 hour period after the first docetaxel treatment. Time points include time 0, 15 minutes, 45 minutes, 180 minutes (3 hours), 390 minutes (6.5 hours), and 1440 minutes (24 hours).

DEXA Scan*

  • DEXA scan will be performed during the patient's stay in the Clinical Research Center, on the Lunar DPXL Bone Densitometer. This is a very simple and noninvasive test which uses x-rays and a computer program to analyze the ratio of 38 keV to 70 keV attenuation. The program then calculates Fat and Lean values for the arms, legs, abdomen, ribs, and the total body. This is the same test that is in widespread clinical use for the evaluation of osteoporosis. During the DEXA scan, patients will be exposed to a trace amount of radiation which is equal to about 2% of the yearly background dose, or less.

    *The amount of radiation to be administered by the erythromycin breath test and DEXA scan is not medically significant.

  • After the first dose of docetaxel, patients will receive docetaxel every 3 weeks

How long a patient continues on chemotherapy will be decided by both the patient and the doctor. If a patient is responding to docetaxel, typically they receive 6-8 doses.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Breast Cancer
  • Drug: Docetaxel
    You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
  • Procedure: Erythromycin Breath Test (ERMBT)
    you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
February 2006
September 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with biopsy proven, measurable metastatic breast cancer. Patients with bone-only, and/or effusion-only disease are excluded.
  • Karnofsky performance status equal to 70 or greater.
  • ANC > 1500, Hgb > 10, plt > 100.
  • Patients with some degree of hepatic dysfunction and renal dysfunction are encouraged, in order to evaluate the ability of the ERMBT in tailoring dose in these patient populations.

Exclusion Criteria:

  • Age less than 18 years.
  • Allergy to erythromycin.
  • Previous treatment with docetaxel. Prior paclitaxel is allowed.
  • Grade > 2 peripheral neuropathy.
  • No confounding factors present to provide misinterpretation of data (i.e., concurrent malignancy).
  • Patients who are pregnant or nursing will not be eligible for this protocol. Women of childbearing age who are not practicing reliable birth control must have a documented negative serum HCG.
  • Patients who require concurrent treatment with drugs which are known to induce or inhibit CYP3A activity will be ineligible for the trial. This list includes the drugs midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide antibiotics (erythromycin and related compounds), nifedipine, anti-seizure drugs, and rifampin (induction).
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00148070
UMCC 9900, GIA#11119, IRBMED 1999-121
Yes
University of Michigan Cancer Center
University of Michigan Cancer Center
  • Aventis Pharmaceuticals
  • Rhone-Poulenc Rorer
Principal Investigator: Anne Schott, MD University of Michigan Cancer Center
University of Michigan Cancer Center
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP